Literature DB >> 25104739

Comment on 'Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy'.

N V Radke1, T K Panakanti2, S N Radke1, R Ravikoti2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25104739      PMCID: PMC4268447          DOI: 10.1038/eye.2014.198

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  3 in total

Review 1.  A review of anti-VEGF agents for proliferative diabetic retinopathy.

Authors:  P Osaadon; X J Fagan; T Lifshitz; J Levy
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

2.  Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy.

Authors:  K Ghasemi Falavarjani; M Hashemi; M Modarres; A Hadavand Khani
Journal:  Eye (Lond)       Date:  2014-02-21       Impact factor: 3.775

Review 3.  Pathophysiology of proliferative vitreoretinopathy in retinal detachment.

Authors:  Justus G Garweg; Christoph Tappeiner; Markus Halberstadt
Journal:  Surv Ophthalmol       Date:  2013-05-02       Impact factor: 6.048

  3 in total
  2 in total

1.  Proliferative vitreoretinopathy and antivascular endothelial growth factor treatment.

Authors:  K Ghasemi Falavarjani; M Modarres
Journal:  Eye (Lond)       Date:  2014-08-08       Impact factor: 3.775

2.  The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy.

Authors:  Rui Zhang; Xin Sun; Bo Niu
Journal:  Exp Ther Med       Date:  2017-10-16       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.